Lescarden Inc. (LCAR)
Lescarden Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3,181. Its beta of -0.72 implies it has historically moved less than the broad market.
Lescarden Inc. operates as a pharmaceutical company, concentrating on the investigation, refinement, and market distribution of medicinal products aimed at managing and curing various illnesses. Its global reach extends across the United States, Europe, and South Korea. The company's premier offering is Catrix Wound Dressing, a product specifically designed for the treatment of persistent lesions, burns, and difficult-to-heal wounds, such as decubitus, venous stasis, and diabetic ulcers. Beyond this, Lescarden provides a range of Catrix-derived solutions for wound and skin care, targeting the aesthetic surgery, dermatological, and medical spa sectors. Furthermore, the organization manufactures dietary supplements, including Bio-Cartilage and Poly-NAG, which is a patented glucosamine polymer. Lescarden also licenses its unique technologies to other enterprises for wider commercial application. Founded in 1960, Lescarden Inc. has its main office situated in New York, New York.
Lescarden Inc. is most often compared with the following Healthcare names: